// App-Quantinova.ai

LB10 : Ofatumumab Effectiveness and Safety in Relapsing Multiple Sclerosis Patients with Breakthrough Disease on Oral Fumarates or Fingolimod: Artios Interim Analysis

Researchers

Presenter

  • Riley Bove

Principal Investigators

  • Matthew Craner

  • Dawn Langdon

  • Daniel Sienkiewicz

  • Javier Ricart

  • Soudeh Ansari

  • Sophie Arnould

  • Ibolya Boer

  • Tobias Derfuss

Medical Centers

  • Novartis Pharma AG

  • Novartis Institutes for BioMedical Research, MA

  • Royal Holloway University of London

  • University Hospital Basel, University of Basel

  • John Radcliffe Hospital, Oxford University Hospitals NHS Trust

  • University of California, San Francisco, CA

  • Novartis Farmacéutica

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • Immunoglobulin G

  • Neurofilament-light chain

Drug/Treatment

  • Fingolimod

  • ofatumumab Intravenous

Outcome

  • Unknown

Study Design

  • Open Label

  • Single Arm

  • Non-Comparative

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved